Final Agenda

Tuesday, June 30, 2020

11:00 a.m. – 5:30 p.m. EDT

Chair:

Robert Schoen, M.D., M.P.H., University of Pittsburgh

Co-Chair:

Brian Haab, Ph.D., Van Andel Institute

NCI Program Directors:

Jo Ann Rinaudo, Ph.D., and Matthew Young Ph.D., National Cancer Institute

11:00 a.m. – 2:00 p.m. EDT Colon and Esophageal:
11:00 a.m. – 11:15 a.m. EDT Welcome and Introduction GI01: Robert Schoen, M.D., M.P.H., University of Pittsburgh,
ctDNA for monitoring of CRC
11:15 a.m. – 11:20 a.m. EDT Q&A
11:20 a.m. – 11:35 a.m. EDT GI02: Kamel Lahouel, Johns Hopkins University,
A statistical method for analyzing circulating tumor DNA
11:35 a.m. – 11:40 a.m. EDT Q&A
11:40 a.m. – 11:55 a.m. EDT GI03: Jason Liggett, Ph.D., EDP Biotech,
Serum based multiplex protein assay for early detection of colorectal cancer and precancerous lesions in a FIT positive population
11:55 a.m. – 12:00 p.m. EDT Q&A
12:00 p.m. - 12:15 p.m. EDT GI04: Paul Lampe, Ph.D., Fred Hutchinson Cancer Research Center,
Update on phase 3 validation of colon cancer markers and the collaborative group project
12:15 p.m. - 12:20 p.m. EDT Q&A
12:20 p.m. – 12:40 p.m. EDT Lunch Break
12:40 p.m. – 12:55 p.m. EDT GI05: Larry LaPointe, Ph.D., Clinical Genomics,
Update on TRIDENT, a three-gene biomarker assay for colorectal neoplasia
12:55 p.m. – 1:00 p.m. EDT Q&A
1:00 p.m. - 1:15 p.m. EDT GI06: Ming Yu, Ph.D., Fred Hutchinson Cancer Research Center,
Methylated EVL is a potential risk biomarker for colorectal cancer
1:15 p.m. - 1:20 p.m. EDT Q&A
1:20 p.m. - 1:35 p.m. EDT GI07: William Grady, M.D., Fred Hutchinson Cancer Research Center,
Biomarkers of Barrett’s Esophagus and esophageal adenocarcinoma
1:35 p.m. - 1:40 p.m. EDT Q&A
1:40 p.m. – 2:00 p.m. EDT SWOT (Strengths, Weaknesses, Opportunities, and Threats) Analysis

Discuss the strengths of EDRN and suggestions to further strengthen the Network
Identify weaknesses and discuss the solutions (Mitigation)
Discuss opportunities and highlight prioritized opportunities
Discuss threats (competing interests/research) and mitigations
2:00 p.m. - 2:15 p.m. EDT Break
2:15 p.m. – 5:30 p.m. EDT PDAC
2:15 p.m. – 2:30 p.m. EDT GI08: Progress in the Development of PDAC Biomarkers: Haab-Brand-Allen BDL
Brian Haab, Ph.D., Van Andel Institute
2:30 p.m. – 2:35 p.m. EDT Q&A
2:35 p.m. – 2:50 p.m. EDT GI09: Validation of Mucin Based Biomarkers for Early Diagnosis of Pancreatic Neoplasms
Surinder Batra, Ph.D., University of Nebraska Medical Center
2:50 p.m. – 2:55 p.m. EDT Q&A
2:55 p.m. – 3:10 p.m. EDT GI10: Lead-time trajectory of CA19-9 as an anchor marker for pancreatic cancer early detection
Johannes Fahrmann, Ph.D., The University of Texas MD Anderson Cancer Center
3:10 p.m. – 3:15 p.m. EDT Q&A
3:15 p.m. – 3:25 p.m. EDT Break
3:25 p.m. - 3:40 p.m. EDT GI11: Update on CVC Collaborations, Supplemental Projects and Team Project 3
Randall Brand, M.D., University of Pittsburgh Medical Center
3:40 p.m. - 3:45 p.m. EDT Q&A
3:45 p.m. - 4:00 p.m. EDT GI12: An Update to the Pancreatic Cyst Biomarker Alliance (PCBA): Is the (cyst) juice worth the squeeze?
Aatur Singhi, M.D., University of Pittsburgh Medical Center
4:00 p.m. - 4:05 p.m. EDT Q&A
4:05 p.m. - 4:20 p.m. EDT GI13: Alliance of Pancreatic Consortia (APaCC): Pre-diagnostic and early stage PDAC imaging repository project
Eugene Koay, M.D., The University of Texas MD Anderson Cancer Center
4:20 p.m. - 4:25 p.m. EDT Q&A
4:25 p.m. - 4:40 p.m. EDT GI14: Pancreatic Cancer Bake-Off Projects Updates
Ying Huang, Ph.D., Fred Hutchinson Cancer Research Center
4:40 p.m. - 4:45 p.m. EDT Q&A
4:45 p.m. - 5:00 p.m. EDT Team Project Group Discussion
5:00 p.m. - 5:30 p.m. EDT SWOT (Strengths, Weaknesses, Opportunities, and Threats) Analysis

Discuss the strengths of EDRN and suggestions to further strengthen the Network
Identify weaknesses and discuss the solutions (Mitigation)
Discuss opportunities and highlight prioritized opportunities
Discuss threats (competing interests/research) and mitigations
5:30 p.m. EDT Adjourn